You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
奧賽康(002755.SZ):子公司注射用蘭索拉唑首家通過一致性評價
格隆匯 12-04 07:54

格隆匯12月4日丨奧賽康(002755.SZ)宣佈,公司的全資子公司江蘇奧賽康藥業有限公司於近日收到國家藥監局核准簽發的注射用蘭索拉唑《藥品補充申請批准通知書》,批准該藥品首家通過仿製藥質量和療效一致性評價。

蘭索拉唑是一種新型質子泵抑制劑(PPI),其抑制胃酸分泌的優勢在於能持續提高胃內pH值,抑酸作用更強,起效快,能全天維持較高的抑酸水平,具有治癒率高、減輕症狀速度更快、副反應少等優點。注射用蘭索拉唑可用於口服療法不適用的伴有出血的十二指腸潰瘍、伴有出血的胃潰瘍、急性應激性潰瘍和急性胃粘膜病變等疾病的治療。

PDB數據庫顯示2019年蘭索拉唑銷售額超20億元,市場規模大。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account